Research
BARE partners with leading organizations and experts in the Biliary Atresia community to advance research initiatives.
.webp)
The EXPAND Study
Living with itch due to cholestatic liver disease
Conducted By: Mirum Pharma
Who Can Participate?
Are 6 months of age or older
Have pruritus (itch) due to a cholestatic liver disease ​
​
About The Study?
-
Mirum pharmaceuticals is currently enrolling in the EXPAND clinical study evaluating an investigational medication called maralixibat as a potential treatment option for pruritus (itch) in pediatric and adult patients with general cholestatic liver disease.
-
Study participation will last about 5 months
-
If travel to the nearest study site is too burdensome, home health visits may be available.
​What is LIVMARLI (Maralixibat)?
LIVMARLI is a medication being tested for kids with biliary atresia. It works by targeting a specific part of your body called the ileal bile acid transporter (IBAT). By doing so, it helps reduce harmful bile acids in the liver and blood. These acids are then safely removed from the body through waste.
​​
Why is This Study Important?
This research aims to find out how effective and safe LIVMARLI is for children with biliary atresia.
Your participation could help us better understand treatment options for this condition.
​
For more information about the EXPAND study, visit the Clinical Trials.gov website: www.clinicaltrials.gov
​
BOLD clinical trial
Join the BOLD Clinical Trial for
Biliary Atresia: Learn About Odevixibat
Conducted By: Albireo Pharma
Study Phase: Phase 3
Study ID: NCT04336722
Want to Learn More?
For more details about this clinical trial, you can visit the NIH Clinical Trial Website.
Interested in participating or have questions? Reach out to their research team.
Contact Details: Phone: +1 (857) 378-2035
Email: medinfo@albireopharma.com
What is Odevixibat?
Odevixibat is a medication specifically designed for babies with biliary atresia who have had a Kasai procedure. It works by targeting a part of the body that helps control bile acids. The medication is easy to administer—it's a once-daily oral dose that can be mixed into breast milk, formula, or certain soft foods.
​
Why is This Study Important?
This is the first Phase 3 study to look at how safe and effective Odevixibat is for babies with biliary atresia. Your participation could help us better understand how to treat this condition more effectively.